NCT07273825Completed
The Effect of Geranium Essential Oil Aromatherapy on Fatigue and Sleep Quality in Patients Undergoing Hemodialysis
Source: ClinicalTrials.gov · Last updated 10 Dec 2025
Brief summary (registry, in English)
Hemodialysis is a life-sustaining therapy for individuals with chronic kidney disease; however, it is often accompanied by adverse effects such as fatigue and poor sleep quality. Fatigue is one of the most frequently reported symptoms among hemodialysis patients and can significantly impair daily functioning, psychosocial wellbeing, and overall quality of life. Sleep disturbances are also common and may further exacerbate physical and emotional stress. Aromatherapy using essential oils has been explored as a non-pharmacological intervention to reduce fatigue and improve sleep quality. Geranium essential oil contains active compounds such as geraniol, citronellol, and terpineol, which possess relaxing, anti-inflammatory, and analgesic properties. These characteristics indicate its potential to alleviate fatigue and promote better sleep. This study aims to evaluate the effect of geranium essential oil aromatherapy on fatigue and sleep quality in patients undergoing hemodialysis. The study employs a randomized cross-over design involving 90 participants who meet predetermined inclusion criteria. Fatigue will be assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F), and sleep quality will be measured using the Pittsburgh Sleep Quality Index (PSQI). Assessments will be conducted before and after the intervention period. The findings of this study are expected to provide scientific evidence supporting the use of geranium essential oil aromatherapy as a safe, accessible complementary therapy that may help reduce fatigue and improve sleep quality among hemodialysis patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 20 Nov 2025
- Start date
- 1 Jan 2025
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Universitas Muhammadiyah Surakarta
- Diseases
- Chronic kidney disease
- NCT number
- NCT07273825
What you commit to
- Study type: Interventional
- Participants enrolled: 90
- From 1 Jan 2025 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of other therapies for fatigue during the intervention period
Other illness
- Presence of respiratory disease.
- History of allergy to perfumes or fragrance products.
- Olfactory impairment (difficulty smelling).
Who the study is looking for
- Adults aged 18-65 years.
- Have no visual or hearing impairments.
- Provide informed consent to participate.
- Have undergone hemodialysis (HD) for at least 3 months.
- Regularly receive HD at the study site.
- Undergo HD at least 2 times per week. 'Experience moderate to severe fatigue.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Health Sciences, Universitas Muhammadiyah Surakarta Coordinator of this site? Confirm its status | Sukoharjo | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.